Nevertheless, the efficacy values presented are consistent with what was reported as significant (or nominally significant) relative to placebo in the respective pivotal studies. 9 , 10 Likewise, the safety profile, which was similar between patients who received placebo or benralizumab in the pivotal studies, 9 , 10 was consistent with what was reported for Year 2 in this study.
← all excerpts
Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma.
1
—
—